Do GLP-1 Drugs Slow Aging? What the Evidence Shows

In female mice, late-life semaglutide extended median lifespan 11%, with no human study showing these drugs extend life.

Semaglutide started late in life extended median lifespan in female mice from 742 to 834 days (+11%) and improved several measures of aging, a peer-reviewed Nature study reports — the only lifespan evidence in this cluster of “anti-aging” GLP-1 stories. The human items are a Novo Nordisk preprint on proteomic “biological age” and unpublished Lilly conference data; neither measured lifespan or death, and no human study has shown these drugs extend life.

What this means

In female mice, semaglutide begun at 20 months — late in a mouse’s life — slowed several hallmarks of aging and extended median lifespan from 742 to 834 days, a 92-day gain resembling calorie restriction. That has not been shown in people. The human “anti-aging” signals are biological-age biomarkers from a non-peer-reviewed, company-run preprint and unpublished conference data with no placebo group, and no trial has shown GLP-1 drugs change human lifespan, and none has shown a reduction in death. Their established human benefits are organ-level, not longer life; treat the human anti-aging question as open.

A cluster of three items, not one study

October 2026 coverage asked whether GLP-1 drugs such as semaglutide are “anti-aging medications,” often blending three items of very different status into one claim. Kept apart: a peer-reviewed animal study in Nature (female mice only); a Novo Nordisk preprint on proteomic “biological age,” not peer reviewed; and unpublished Eli Lilly conference data on epigenetic clocks, with no placebo comparator, no paper and no DOI. None measured human lifespan.

What the mouse study found

Feng and colleagues gave 20-month-old female C57BL/6 mice — by common mouse-to-human age conventions, roughly the equivalent of a 60-year-old person — saline or semaglutide for life (39 controls, 40 treated). Median lifespan was 742 days in controls and 834 days with semaglutide, a 92-day difference (Fig. 1a). The paper reports median, not average, lifespan; no hazard ratio or confidence interval was reported. Semaglutide cut food intake by 24% without significantly changing locomotor activity or energy expenditure.

At three months, treated mice moved and explored more, performed better on a Barnes maze (a learning-and-memory test), had stronger motor and muscle function, and handled glucose better. Several hallmarks of aging were attenuated: fewer hematopoietic stem cells, more new neurons in the hippocampus, and lower markers of cell senescence and inflammation. Against a 24% calorie-restricted group over five months (10 mice per group), semaglutide and calorie restriction moved similarly on several functions; semaglutide was better for open-field center time (exploratory drive), the Barnes maze and glucose tolerance.

The human “anti-aging” items are biomarker signals

The Novo Nordisk preprint, posted on Research Square on 22 September 2026, analyzed proteomic, organ-specific “biological age” across five semaglutide trials and 10,052 participants. It reported a heart biological age 2 to 4 years younger than placebo, and 1 to 4 years across kidney, brain, pancreas and lung. It is not peer reviewed, and its authors state it does not establish rejuvenation, causal mediation, or that these surrogate markers track real health outcomes.

The Lilly item is conference data from SURMOUNT-V: CNN reported that epigenetic clocks in 71 tirzepatide-treated participants over 50 advanced 0.7 to 1.1 years, where 1.38 years was expected. It is unpublished, with no placebo comparator and no paper or DOI. Both human items are biomarker proxies, not measured lifespan or death, so neither can show a drug slows aging.

What is established in humans

Two large randomized trials show organ-level benefits for semaglutide: SELECT found fewer cardiovascular events in adults with overweight or obesity, no diabetes, and established cardiovascular or kidney disease, and FLOW found kidney benefits in people with type 2 diabetes and chronic kidney disease. Neither addressed lifespan or an aging endpoint; the human base is organ-level benefit, not life extension.

The limits of this evidence

The lifespan result is preclinical and narrow: female C57BL/6 mice only, one sex and one strain, so it may not generalize to males or people. No human study has shown that GLP-1 drugs extend lifespan or reduce death. The human items are biomarker proxies from drug sponsors — developing clocks, a preprint, and conference-only data with no placebo group. That semaglutide acts as a calorie-restriction mimetic is hypothesis-level, tested at one restriction level; whether longevity diets extend human life is itself unsettled (does-a-longevity-diet-work-in-humans). And people do not all respond to GLP-1 drugs the same way (why-do-glp-1-weight-loss-drugs-work-differently-for-different-people).

Funding, patents and sponsor interests

The Nature study was funded by US National Institutes of Health grants R01AG063404, R01AG063389 and R01AG082105 and the USDA National Institute of Food and Agriculture. The paper discloses that the Regents of the University of California filed a patent application on GLP-1 receptor agonists for healthy aging (64/113,481) — a direct intellectual-property interest in the anti-aging claim. The Novo preprint and Lilly data are corporate products: Novo Nordisk makes semaglutide and Eli Lilly makes tirzepatide, so each concerns its own drug.

Terms explained

GLP-1 receptor agonist: an injectable drug such as semaglutide or tirzepatide that mimics a gut hormone released after eating; it slows stomach emptying and reduces appetite, lowering food intake and body weight.
Healthspan vs lifespan: healthspan is how long someone stays healthy and free of frailty; lifespan is how long they live. The mouse study reported both; the human items neither.
Biological age and epigenetic clock: biological age estimates how old a body seems to be from markers rather than calendar years; an epigenetic clock reads chemical tags on DNA that tend to change with age. Whether a clock change reflects real health or lifespan change is unestablished.
Calorie-restriction mimetic: a compound that produces some effects of eating less without cutting calories. The paper describes semaglutide’s pattern as resembling calorie restriction; that comparison is hypothesis-level.
Preprint (not peer reviewed): a manuscript posted publicly, often by its authors, before independent experts have reviewed it. The Novo preprint’s numbers should be read as provisional.

Sources

Primary source (peer-reviewed; preclinical, mouse): Feng Y, Barthez M, Wang Y, Chen Y, Qiu H, Wang C-L, Heydari K, Delcroix M, Rasmussen LJ, Bohr VA, Chen D. “Late-life semaglutide treatment slows ageing and extends lifespan in female mice.” Nature 2026; published 2026-09-02. DOI: 10.1038/s41586-026-10940-7 · PMID: 42686906. Peer-reviewed animal study (female C57BL/6 mice). PMCID: PMC13558073. Note: the journal title retains the spelling “ageing.”
Prior mouse reference (peer-reviewed; full text): Di Francesco A et al. “Dietary restriction impacts health and lifespan of genetically diverse mice.” Nature 2024. DOI: 10.1038/s41586-024-08026-3.
Adjacent human trials (peer-reviewed; abstract-level access): Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” NEJM 2023. DOI: 10.1056/NEJMoa2307563. · Perkovic V et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.” NEJM 2024. DOI: 10.1056/NEJMoa2403347.
Human biomarker analysis — NOT peer reviewed (company preprint): Dermit M et al. (Novo Nordisk). “Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials.” Research Square preprint, posted 2026-09-22; not peer reviewed; industry-produced. DOI: 10.21203/rs.3.rs-11082091/v1.
Human biomarker analysis — unpublished conference data (no paper, no DOI): Eli Lilly SURMOUNT-V epigenetic-clock subgroup, reported at the ARDD conference and covered by CNN Health, 2026-10-13; conference-only, no placebo comparator, identity limited to the CNN/ARDD report. https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging